(Q44117294)

English

Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group

scientific article published in September 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 November 2017

Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group (English)

1 reference

Europe PubMed Central

30 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

object named as

Per Ljungman

1 reference

Europe PubMed Central

30 November 2017

author name string

Ulla Axdorph

1

1 reference

Europe PubMed Central

30 November 2017

Leif Stenke

2

1 reference

Europe PubMed Central

30 November 2017

Gunnar Grimfors

3

1 reference

Europe PubMed Central

30 November 2017

Jan Carneskog

4

1 reference

Europe PubMed Central

30 November 2017

Jan Hansen

5

1 reference

Europe PubMed Central

30 November 2017

Olle Linder

6

1 reference

Europe PubMed Central

30 November 2017

Eva Löfvenberg

8

1 reference

Europe PubMed Central

30 November 2017

Claes Malm

9

1 reference

Europe PubMed Central

30 November 2017

Bengt Simonsson

10

1 reference

Europe PubMed Central

30 November 2017

Ingemar Turesson

11

1 reference

Europe PubMed Central

30 November 2017

Lars Vilén

12

1 reference

Europe PubMed Central

30 November 2017

Anne-Marie Udén

13

1 reference

Europe PubMed Central

30 November 2017

Magnus Björkholm

14

1 reference

Europe PubMed Central

30 November 2017

Swedish CML Group

15

1 reference

Europe PubMed Central

30 November 2017

language of work or name

0 references

publication date

1 September 2002

1 reference

Europe PubMed Central

30 November 2017

British Journal of Haematology

1 reference

Europe PubMed Central

30 November 2017

118

1 reference

Europe PubMed Central

30 November 2017

4

1 reference

Europe PubMed Central

30 November 2017

1048-1054

1 reference

Europe PubMed Central

30 November 2017

High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

'Lymphoid' blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Karyotypic findings as an independent prognostic marker in chronic myeloid leukaemia blast crisis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Autologous blood stem cell transplantation followed by recombinant alpha interferon as treatment for patients with high-risk chronic myelogenous leukemia. A report of 32 cases.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG).

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03765.X

21 January 2018

Identifiers

10.1046/J.1365-2141.2002.03765.X

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44117294&oldid=2106753910"